Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Schizophrenia endophenotypes as treatment targets.

Thaker GK.

Expert Opin Ther Targets. 2007 Sep;11(9):1189-206. Review.

PMID:
17845145
3.

The search for novel antipsychotics: pharmacological and molecular targets.

Sanger DJ.

Expert Opin Ther Targets. 2004 Dec;8(6):631-41. Review.

PMID:
15584867
4.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Review.

PMID:
22584864
5.

Antipsychotic drug action: targets for drug discovery with neurochemical imaging.

Stone JM, Pilowsky LS.

Expert Rev Neurother. 2006 Jan;6(1):57-64. Review.

PMID:
16466312
6.
7.

The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia.

Liu SK, Fitzgerald PB, Daigle M, Chen R, Daskalakis ZJ.

Biol Psychiatry. 2009 Mar 15;65(6):503-9. doi: 10.1016/j.biopsych.2008.09.012. Epub 2008 Oct 31.

PMID:
18950746
8.
9.

[The utility of an endophenotype approach in overcoming the difficulties in bipolar and schizophrenia genetics].

Ozer S, Ayhan Y, Uluşahin A.

Turk Psikiyatri Derg. 2004 Summer;15(2):125-37. Review. Turkish.

10.

Model-based gene selection shows engrailed 1 is associated with antipsychotic response.

Webb BT, Sullivan PF, Skelly T, van den Oord EJ.

Pharmacogenet Genomics. 2008 Sep;18(9):751-9. doi: 10.1097/FPC.0b013e32830162bc.

PMID:
18698228
11.

Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Honer WG, Thornton AE, Sherwood M, MacEwan GW, Ehmann TS, Williams R, Kopala LC, Procyshyn R, Barr AM.

CNS Drugs. 2007;21(9):699-714. Review.

PMID:
17696571
12.

Antipsychotic drug actions on gene modulation and signaling mechanisms.

Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA.

Pharmacol Ther. 2009 Oct;124(1):74-85. doi: 10.1016/j.pharmthera.2009.06.001. Epub 2009 Jun 21. Review.

PMID:
19540875
13.

Development of novel antipsychotic drugs.

Tallman JF.

Brain Res Brain Res Rev. 2000 Mar;31(2-3):385-90. Review.

PMID:
10719166
14.

Brain connectivity and gyrification as endophenotypes for schizophrenia: weight of the evidence.

White T, Gottesman I.

Curr Top Med Chem. 2012;12(21):2393-403. Review.

PMID:
23279178
15.

Schizophrenia: from phenomenology to neurobiology.

Wong AH, Van Tol HH.

Neurosci Biobehav Rev. 2003 May;27(3):269-306. Review.

PMID:
12788337
16.
17.
18.

Role of the cholinergic system in the pathology and treatment of schizophrenia.

Scarr E, Dean B.

Expert Rev Neurother. 2009 Jan;9(1):73-86. doi: 10.1586/14737175.9.1.73. Review.

PMID:
19102670
19.

Schizophrenia: moving beyond monoamine antagonists.

Conn PJ, Tamminga C, Schoepp DD, Lindsley C.

Mol Interv. 2008 Apr;8(2):99-107. doi: 10.1124/mi.8.2.7. Review.

PMID:
18403654
20.

The effect of change in clinical state on eye movement dysfunction in schizophrenia.

Kallimani D, Theleritis C, Evdokimidis I, Stefanis NC, Chatzimanolis I, Smyrnis N.

Eur Psychiatry. 2009 Jan;24(1):17-26. doi: 10.1016/j.eurpsy.2008.08.003. Epub 2008 Oct 14.

PMID:
18922684

Supplemental Content

Support Center